ABVX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

8 Analyst Rating

Wall Street analysts forecast ABVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVX is 129.25 USD with a low forecast of 101.00 USD and a high forecast of 176.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

101.00

Averages

129.25

High

176.00

Current: 0.000

Low

101.00

Averages

129.25

High

176.00

BTIG

Julian Harrison

Buy

maintain

$120 -> $150

2026-01-08

New

Reason

BTIG

Julian Harrison

Price Target

$120 -> $150

2026-01-08

New

maintain

Buy

Reason

BTIG analyst Julian Harrison raised the firm's price target on Abivax to $150 from $120 and keeps a Buy rating on the shares. Abivax provided an updated 2026 pipeline outlook highlighting strong Phase 3 ABTECT induction data for obefazimod, positioning it as a preferred, flexible oral option across the moderate-to-severe treatment paradigm, with no new safety signals reported to date, the analyst tells investors in a research note.

Guggenheim

Yatin Suneja

Buy

maintain

$150 -> $175

2025-12-18

Reason

Guggenheim

Yatin Suneja

Price Target

$150 -> $175

2025-12-18

maintain

Buy

Reason

Guggenheim analyst Yatin Suneja raised the firm's price target on Abivax to $175 from $150 and keeps a Buy rating on the shares based on the firm's "optimistic outlook" for obefazimod in the 44-week maintenance readout that is upcoming.

Piper Sandler

NULL -> Overweight

maintain

$112 -> $142

2025-12-16

Reason

Piper Sandler

Price Target

$112 -> $142

2025-12-16

maintain

NULL -> Overweight

Reason

Piper Sandler raised the firm's price target on Abivax to $142 from $112 and keeps an Overweight rating on the shares.

Citizens

Outperform

maintain

$114 -> $131

2025-12-16

Reason

Citizens

Price Target

$114 -> $131

2025-12-16

maintain

Outperform

Reason

Citizens raised the firm's price target on Abivax to $131 from $114 and keeps an Outperform rating on the shares. Abivax reported Q3 results and business updates, highlighting positive Phase 3 ulcerative colitis data announced in August that continue to support a potentially practice-changing profile, the analyst tells investors in a research note. The company expects Phase 3 maintenance results in 2Q26 and Phase 2b Crohn's disease data in the second half of 2026.

Truist

Gregory Renza

Buy

initiated

$140

2025-11-24

Reason

Truist

Gregory Renza

Price Target

$140

2025-11-24

initiated

Buy

Reason

Truist analyst Gregory Renza initiated coverage of Abivax with a Buy rating and $140 price target. Following a second-half re-rate from phase 3 induction data in ulcerative colitis, investors are focused on obefazimod's increasing value proposition and set-up for key phase 3 UC maintenance data in Q2 of 2026 and phase 2b induction topline in Crohn's disease coming the second half of 2026, the analyst tells investors in a research note. Obefazimod represents an unusual mechanism of action, which the firm views as being backed by preclinical and clinical evidence indicating broad immunological effects, Truist added.

Wolfe Research

Outperform

initiated

$176

2025-11-05

Reason

Wolfe Research

Price Target

$176

2025-11-05

initiated

Outperform

Reason

Wolfe Research initiated coverage of Abivax with an Outperform rating and $176 price target. The company's odds of success in Crohn's disease may be higher than that of ulcerative colitis, the analyst tells investors in a research note. The firm says that with ulcerative colitis already succeeding, and with obefazimod having a better mechanism for Crohn's disease, the Crohn's readout is a better catalyst in 2026.

Valuation Metrics

The current forward P/E ratio for Abivax SA (ABVX.O) is -41.67, compared to its 5-year average forward P/E of -8.34. For a more detailed relative valuation and DCF analysis to assess Abivax SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.34

Current PE

-41.67

Overvalued PE

4.28

Undervalued PE

-20.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-13.65

Current EV/EBITDA

-41.04

Overvalued EV/EBITDA

14.26

Undervalued EV/EBITDA

-41.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

275.36

Current PS

295.08

Overvalued PS

962.76

Undervalued PS

-412.03

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ABVX News & Events

Events Timeline

No data

News

9.0

14:03 PMNASDAQ.COM

ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis

8.5

13:03 PMCNBC

Abivax Expected to Be Acquired with Valuation Up to €23 Billion

8.5

12:41 PMNewsfilter

Abivax Shares Surge 1,681%, Potential Acquisition Valued at $23 Billion

People Also Watch

Frequently Asked Questions

What is Abivax SA (ABVX) stock price today?

The current price of ABVX is 115.86 USD — it has increased 0.32 % in the last trading day.

What is Abivax SA (ABVX)'s business?

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

What is the price predicton of ABVX Stock?

What is Abivax SA (ABVX)'s revenue for the last quarter?

Abivax SA revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is Abivax SA (ABVX)'s earnings per share (EPS) for the last quarter?

Abivax SA. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Abivax SA (ABVX)'s fundamentals?

The market is revising Upward the revenue expectations for ABIVAX Société Anonyme (ABVX) for FY2025, with the revenue forecasts being adjusted by 15.86% over the past three months. During the same period, the stock price has changed by 28.02%.

How many employees does Abivax SA (ABVX). have?

Abivax SA (ABVX) has 0 emplpoyees as of January 09 2026.

What is Abivax SA (ABVX) market cap?

Today ABVX has the market capitalization of 9.00B USD.